<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIM: To identify factors associated with nocturnal <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> who were new (&lt; 2 months therapy) to insulin therapy </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: A randomised, multicentre, 12-month parallel open-label study compared the clinical safety and efficacy of insulin lispro with regular human insulin </plain></SENT>
<SENT sid="2" pm="."><plain>A cohort of North American patients completed a health-related quality of life (HRQOL) questionnaire which included questions related to the Health Beliefs Model (HBM) </plain></SENT>
<SENT sid="3" pm="."><plain>Measurements of <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> rate and short-and long-term <z:chebi fb="105" ids="17234">glucose</z:chebi> control assessed clinical safety and efficacy </plain></SENT>
<SENT sid="4" pm="."><plain>Three hundred and sixty-five type 2 diabetic patients were enrolled in the study, and 195 North American patients completed the HRQOL questionnaire </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: After adjustment for demographic and psychological factors, the study population demonstrated lower nocturnal <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> risk with insulin lispro </plain></SENT>
<SENT sid="6" pm="."><plain>Higher nocturnal <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> risk was associated with <z:mp ids='MP_0006086'>reduced body mass index</z:mp> (b.m.i.), lower age, and basal ultralente insulin therapy </plain></SENT>
<SENT sid="7" pm="."><plain>The associated <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> risk was lower with <z:mp ids='MP_0003545'>increased alcohol consumption</z:mp> </plain></SENT>
<SENT sid="8" pm="."><plain>Patients who completed the HRQOL survey demonstrated higher risk for nocturnal <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> if they: (1) had more troublesome <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e> symptoms in the week before starting insulin; (2) were more confident in their ability to control their <z:mp ids='MP_0002055'>diabetes</z:mp>; or (3) thought that <z:mp ids='MP_0002055'>diabetes</z:mp> control did not offer a clear health benefit </plain></SENT>
<SENT sid="9" pm="."><plain>Nocturnal <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> risk was inversely associated with fear of <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: Type 2 diabetic patients new to insulin therapy demonstrated lower risk of nocturnal <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> with insulin lispro </plain></SENT>
<SENT sid="11" pm="."><plain>Practitioners should consider patient characteristics and psychological factors that may predispose type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> patients to nocturnal <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> when initiating insulin therapy </plain></SENT>
</text></document>